Trulance (palovarotene) is a medication used to treat fibrodysplasia ossificans progressiva (FOP) [1][2]. FOP is a rare genetic disorder that causes bone to form in soft tissues such as ligaments and tendons [2][3]. This abnormal bone formation can restrict movement by locking joints [3].
When might Trulance be prescribed for FOP?
Trulance is prescribed to reduce the incidence of new heterotopic ossification (HO) in adults and children aged 12 and older with FOP [1]. Heterotopic ossification is the formation of new bone in soft tissues [3].
How does Trulance work?
Trulance is an oral retinoic acid receptor gamma (RARγ) agonist [1][4]. It works by targeting the abnormal bone formation process associated with FOP [4].
What are the potential side effects of Trulance?
Common side effects reported with Trulance include dry mouth, hair loss, dry skin, and inflammation of the lips [1]. It is important for patients to discuss potential risks and side effects with their healthcare provider [1].
How long does Trulance take to be effective?
The provided information does not specify the exact timeline for Trulance's effectiveness. However, it is indicated for reducing the incidence of new heterotopic ossification, suggesting a longer-term management approach rather than immediate symptom relief [1].
What is the drug patent status for Trulance?
Drug patents for Trulance are managed by Ipsen Biopharmaceuticals [5]. Information regarding specific patent expirations and any associated challenges can be found on resources like DrugPatentWatch.com [5].